Alkem Laboratories Reports Q2FY27 Results with 13.8% Revenue Growth
Alkem Laboratories Ltd · Investor Presentation · 12 Nov 2026, 7:28 pm
Alkem Laboratories Reports Q2FY27 Results with 13.8% Revenue Growth Alkem Laboratories reported Q2FY27 revenue of ₹45,520 mn, up 13.8% YoY, supported by India sales growing 9.5% YoY to ₹30,275 mn and international sales surging 22.3% YoY to ₹14,540 mn. EBITDA rose 11.3% YoY to ₹10,252 mn with margins contracting 50 bps YoY to 22.5% due to Enzene CDMO operating costs and Occlutech integration. PAT dropped 11.7% YoY to ₹6,753 mn on higher effective taxes. Net cash stood at ₹49,054 mn as of 30th Sep'26. Mandva API facility cleared US FDA inspection with zero observations.
Original exchange filing (PDF)
More announcements from Alkem Laboratories Ltd
- Please find attached herewith Q2 H1FY2027 - Earnings Conference Call Transcript · 18 Nov 2026
- With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the '' Q2 and H1FY27 Earnings Conference Call'' .... · 13 Nov 2026
- We wish to inform you that the Company has appointed Mr. Gopal Kothari as the CFO and KMP of the Company wef 2nd Dec, 2026. · 12 Nov 2026
- Pl find enclosed unaudited financial results along with Limited Review Report of the Company for quarter and half year ended 30th Sept, 2026. · 12 Nov 2026
- Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 12 Nov 2026
- Please find enclosed herewith the outcome of Board meeting dated 12th Nov, 2026. The meeting of the Board of Directors of the Company commenced at 11.30 am and concluded at 13.40. · 12 Nov 2026
- Please find attached herewith intimation of incorporation of subsidiary in the form of Joint Venture. · 09 Nov 2026
- With reference to your email regarding the captioned corporate announcement submitted by the Company on 03rd November, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure .... · 05 Nov 2026
